Current uses of chlorhexidine for management of oral disease: a narrative review by Brookes, Zoe L. S. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Current uses of chlorhexidine for management of oral disease: a
narrative review
Author(s) Brookes, Zoe L. S.; Bescos, Raul; Belfield, Louise A.; Ali, Kamran;
Roberts, Anthony
Publication date 2020-10-17
Original citation Brookes, Z. L. S., Bescos, R., Belfield, L. A., Ali, K. and Roberts,
A.(2020) 'Current uses of chlorhexidine for management of oral disease:
a narrative review', Journal of Dentistry, 103, 103497 (9pp). doi:
10.1016/j.jdent.2020.103497




Access to the full text of the published version may require a
subscription.
Rights © 2020, Elsevier B.V. All rights reserved. This manuscript version is
made available under the CC BY-NC-ND 4.0 license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.






Current uses of chlorhexidine for management of oral disease: a
narrative review





To appear in: Journal of Dentistry
Received Date: 16 July 2020
Revised Date: 4 October 2020
Accepted Date: 10 October 2020
Please cite this article as: {doi: https://doi.org/
This is a PDF file of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
definitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its final form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2020 Published by Elsevier.




Current uses of chlorhexidine for management of oral disease: 
a narrative review 
 
Zoë L. S..Brookesa, Raul Bescosb, Louise A. Belfielda, Kamran Alia, Anthony Robertsc  
 
Dr Zoë Brookes, Clinical Lecturer in Dentistry, Dental Associate 
Dr Raul Bescos, Lecturer in Human Physiology 
Dr Louise Belfield, Lecturer in Biomedical Sciences 
Professor Kamran Ali, Professor of Dental Education, Consultant Oral Surgeon 
Professor Anthony Roberts, Professor of Restorative Dentistry 
 
a  Peninsula Dental School, University of Plymouth, Plymouth, PL4 8AA, UK 
b School of Health Professions, University of Plymouth, Plymouth, PL4 8AA, UK 
c Cork University Dental School and Hospital/UCC, Wilton, Cork, T12 E8YV, Ireland 
 
Corresponding author: 
Dr Zoë Brookes BSc (Hons), BDS, MJDF (RCS Eng), PCHE, SFHEA, PhD 
Clinical Lecturer  




Tel: 01752 586828 
 
Short title: chlorhexidine and oral disease 
 
Abstract 
Objectives: Chlorhexidine (CHX) is a commonly used antiseptic mouthwash, used by dental 
practitioners and the public, due to its antimicrobial effects. The aim of this article was to provide a 
narrative review of current antimicrobial uses of CHX relevant to dentistry in the context of oral 
diseases, highlighting need for further studies to support its safe and appropriate use. 
Study selection, data and sources: Randomised controlled trials, systematic reviews and national 
(UK and US) guidelines  were consulted where available, with search terms for each subject 
category entered into MEDLINE, PubMed, Google Scholar and the Cochrane database.  
Results: Some evidence existed to support adjunctive short-term use of CHX to manage dental 
plaque, and reduce clinical symptoms of gingivitis, dry socket, as well as reduce aerosolisation of 
bacteria. However, use must be weighed alongside the less desirable effects of CHX, including 
extrinsic staining of teeth, antimicrobial resistance to antiseptic agents and the rare, but fatal, 













prevent periodontitis, dental caries, necrotising periodontal diseases, peri-implantitis, and infections 
associated with extraction and aerosolised viruses remains less certain.  
Conclusions: The use of CHX in dentistry and oral healthcare continues to be widespread and thus 
it is important that dental practitioners understand that, based on its differential mechanisms of 
action on different microbes, appropriate clinical and dental use of CHX should be oral disease 
specific. However, further scientific and clinical research is required before full recommendations 
can be made. 
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Introduction 
Chlorhexidine gluconate (1,1'-hexamethylene bi  [5-(p-chlorophenyl) biguanide] di-D-gluconate) 
(CHX) is a gluconate salt; a biguanide compound, that has been around since the 1950s for clinical 
use. It is also a broad-spectrum anti-microbial agent, causing disruption of cellular membranes [1]. 
It is thus currently used as a disinfectant agent for cleaning non-living clinical surfaces and 
catheters. It is also generally biocompatible, being used orally as an antiseptic mouthwash by 
dental practitioners and the general public to prevent bacterial biofilm and plaque accumulation [2]. 
The latter are potentially causative for dental caries, plaque-induced gingivitis, periodontitis and 
oral soft tissue disease. Nevertheless, as discussed henceforth, CHX has differing effects on 
bacteria, viruses and fungi, and the potential to have more clinical benefit with some oral diseases 
than others. The aim of this article therefore, was to provide a narrative review of current 
antimicrobial uses of CHX relevant to dentistry, especially in the context of oral diseases caused by 
microbes, highlighting need for further studies to support its safe and appropriate use. Search 
terms for each subject category were entered into MEDLINE, PubMed, Google Scholar and the 
Cochrane database. The hierarchical system of evidence based medicine was then applied 
through the review, such that Cochrane review and systematic reviews with randomised trials were 
used as evidence supporting CHX use, followed by individual randomised controlled trials [3]. If 
only individual case controlled or laboratory based studies were available these were then 
reported. National guidelines were also included to provide a sense of current opinion. This article 
was not intended to be a systematic review and therefore recommendations were not made as 
such. This was largely because more research is required in this field, and we consider that this 
article importantly uses the best available evidence to demonstrate this need. 
 
Formulations and uses  
 
For oral use CHX comes in several different formulations. In the United Kingdom (UK) and Europe 
0.2% CHX mouthwash (CorsodylTM) is available over the counter (OTC), as either an alcohol-
containing or non-alcohol formulation. 0.2% tends to be recommended for short-term intensive 













prescribed as a 0.12% mouthwash (ParoexTM). For all mouth rinse formulations, the advice is to 
rinse with 10ml twice daily for 30 seconds, but under 12 years it is use only to be used on the 
advice of a healthcare professional (under 18 years in the US). It is also advised for short-term use 
only; 2-4 weeks, only being licensed for 30 days of use in the UK [4,5]. In patients with oral 
candida, dentures may also be soaked in CorsodylTM mouthwash once or twice daily for 15 
minutes [6]. 
 
CHX mouthwash is near-neutral solution (pH range 5-7), only advised for topical use, and never for 
systemic administration. Being cationic, it binds to skin, mucosa and tissues, which in turn make it 
poorly absorbed across these membranes. After a single rinse, 30% may remain in saliva for up to 
5 hours, and on the oral mucosa for up to 12 hours, with plasma levels being undetectable [7,8]. 
This is because CHX is poorly absorbed from the gastrointestinal tract, even when large volumes 
are ingested. It is generally considered safe for oral use, but some side effects and complications 
have been reported, as later eluded to. 
 
For oral use, CHX digluconate is also available in gel formulations, for example, 1% CHX 
(CorsodylTM), 0.2% CHX (Perio KinTM) and 0.5% CHX (CuraseptTM) gel being available for oral use 
in the UK, including OTC. These gels can also contain other chemicals that assist with muco-
adhesion, for example carboxymethyl- (CMC), hydroxypropylmethyl- (HPMC) and hydroxypropyl- 
(HPC) cellulose in varying combinations. 2% CHX gels or ointments may be used on the skin, and 
this may actually preferred to 70% alcohol or povidone-iodine when applied prior to insertion of 
venous catheters [9]. Much like mouthwash, these oral gels can be used topically for management 
of caries and as an adjunct to mechanical plaque control for gingivitis and periodontitis as well as 
for use for oral candida (including denture stomatitis, applied to the denture surface and or the oral 
mucosa) and aphthous ulcers. In these situations, approximately 2cm of gel may be applied to the 
site once or twice daily. CHX sprays (0.14 ml of 0.2% CorsodylTM) may also be applied twice daily 
to gingival or mucosal surfaces, to treat gingivitis, candidiasis and ulcers in a similar manner. 
 
In addition, available to oral and dental clinicians are PeriochipTM or PerioCol™-CG, formulated as 
biodegradable ‘chips’, soaked in 2.5 mg of CHX digluconate, which can be inserted into  
periodontal pockets in combination with sub-gingival debridement. These products may produce 
better clinical outcomes for periodontitis patients, although their success has yet to be fully 
elucidated [10,11]. The numbers of other CHX dental products continue to expand, to currently 
include toothpastes with 0.05% CHX, such as CurapseptTM and CorsodylTM. These are also sodium 
lauryl sulphate-free (SLS free), the foaming agent, known to be an allergen and cause mucosal 
irritation and desquamation in some patients [12]. Toothbrushes and floss coated in CHX are also 
now commercially available. However, no appropriate meta-analyses or systematic reviews of the 















As an antiseptic mouthwash, CHX has an anti-microbial effect on bacteria, fungus and viruses 
causative for a number of different oral diseases. In vitro, the anti-bacterial effects of CHX all relate 
to altered cell membrane permeability [1]. At low concentrations (0.02%-0.06%) CHX causes 
displacement of Ca2+and Mg2+ and loss of K+ from the cell wall, resulting in a bacteriostatic effect 
[1,13]. At high concentrations (>0.1%) CHX causes leakage of all the main intracellular 
components out of the cell, resulting in a bactericidal (cell lysis and death) effect [1,13]. The anti-
viral effects of CHX are also due to altered cell membrane permeability and ultimately CHX can 
inactivate enveloped viruses, such as herpes simplex virus, which are associated with cold sores 
[14,15]. However, CHX has little virucidal activity on non-enveloped viruses, including HUMAN 
papilloma viruses (HPV), which may be associated with oral cancers [15,16]. The anti-fungal 
effects of CHX however, relate to the prevention of biofilm formation on both biological and non-
biological surfaces, by species such as Candida, rather than disrupting the structure or cellular 
membrane of the microbe. For example, CHX can reduce the amount of Candida albicans 
adhering to the surface of dentures [17], as well decrease the numbers of Candida albicans 
residing on soft tissues in vivo, such as the oral mucosa [18].  
 
The communities of bacteria, fungi and viruses residing within different niches of the oral cavity 
comprise the oral microbiome [19,20]. A diverse oral microbiome is essential for maintaining good 
oral (and systemic) health [20]. However, when it becomes less diverse, for example with 
antiseptics such as CHX, it can become dysbiotic [20,21]. Bacterial oral dysbiosis and has been 
linked to oral diseases, including caries, periodontitis, oral cancer, peri-implantitis and mucosal 
diseases [19]. Thus, in recent years, the potential for CHX to induce dysbiosis, including increased 
prevalence of disease-causing species in vivo [21], has come to be considered just as important 
direct bactericidal effect of CHX reported in the laboratory in vitro [1,12]. Thus, whilst full 
exploration is beyond the scope of the current manuscript, understanding of the oral microbiome is 
important for any discussion of the anti-microbial effects of CHX in vivo. 
 
Side effects, contraindications and allergic reactions 
 
Returning to clinical uses, CHX as a mouthwash or topical oral gel is not without adverse effects, 
some of the most common being dry mouth (xerostomia), altered taste sensations (hypogeusia), 
specifically salt and bitter, and a discoloured or coated tongue. Despite anti-plaque properties, 
increased calculus formation has also been reported with 0.12% CHX mouthwash [22]. Other less 
common side effects include burning sensations (glossodynia), desquamation of the oral mucosa, 
swelling of the parotid gland and oral paraesthesia [23]. However the most unwanted outcome, that 
deters patients using of CHX mouthwash, is probably tooth staining [24]. This is common once 
usage exceeds more than several weeks, due to non-enzymatic browning (Maillard reaction) and 
the production of pigmented metal sulphide formation in the pellicle [25]. This in turn can also allow 
tin and iron binding reactions with dietary aldehydes and ketones that enhances precipitation of 













tooth staining, for example 0.2% Curasept ADSTM, where an anti-discoloration system (ADS) has 
been added to reduce tooth surface staining, via inhibition of the Maillard reaction and protein 
denaturation. There is also now evidence from systematic review that ADS does not effect the 
ability of CHX to reduce to gingival inflammation and plaque scores [27].  
 
The more potentially serious side effects associated with the oral use of CHX are the possible 
Type IV and Type I hypersensitivity reactions accompanied by severe anaphylaxis. For CHX, these 
are reported at an incidence of 0.78 per 100,000 exposures [28,29]. There are also case studies 
reporting that CHX mouthwash can lead to respiratory arrest and death due to severe anaphylactic 
responses [30]. Hence, although rare, and of limited numbers, such reported allergic reactions 
have influenced the usage of CHX amongst clinicians in recent years, and must have some 
bearing when considering risk versus benefit for appropriate use of CHX in the management of all 
relevant oral conditions. It is unlikely that these reactions are associated with any other 
components within the mouthwash, which comprises of Glycerol, Macrogolglycerol 
Hydroxystearate, Sorbitol liquid (non-crystallising) and purified water, although some formations do 
contain menthols that does have the potential to irritate mucosal tissues in rare cases [31]. In the 
UK, the current British National Formulary (BNF) guidelines do not contra-indicate the use of CHX 
in pregnancy, and commercial data sheets have not identified any adverse effects on the foetus. 
However it is suggested that mothers may choose to avoid those formulations containing alcohol. 
The advice is more cautious in the US, as the Food and Drug Agency (FDA) state that CHX may 
be best avoided, especially PeriochipTM, due to the lack of evidence confirming its use is safe 
during pregnancy and breast feeding.  
 
Another emerging issue with CHX is that of Antimicrobial resistance (AMR), whereby the micro-
organisms it is designed to kill, adapt and become resistant, which means that the mouthwash 
becomes less effective [32]. There are several mechanisms by which this may occur, including 
mutation in or the addition of genetic material, leading to changes in cell membrane structure 
(increased expression of efflux pumps) and promoting the cross-resistance of other bacteria to 
antibiotics, including amongst the most multi-drug resistant species [14,33,34]. In addition to 
allergies and staining, AMR must also therefore be considered when recommending CHX use.  
 
Uses for oral disease 
 
CHX is used broadly in dentistry and common usage includes (but is not limited to) (i) the 
management of oral hygiene, dental plaque and caries with or without underlying conditions; (ii) to 
assist in the management of gingivitis, periodontitis and peri-implant disease; (iii) as an irrigant 
during root canal therapy; (iv) management of oral surgery and associated complications; (v) 
management of oral mucosal disease and (vi) as a pre-rinse to reduce aerosolisation of microbes 
during dental procedures. These applications can involve use by the public as an over the counter 

















Dental caries involves the build-up of plaque, containing bacteria such as Streptococcus mutans 
and lactobacilli spp that produce lactic acid in the presence dietary carbohydrates, to cause 
dissolution of tooth enamel and dentine [35]. In the UK CHX (CorsodylTM 0.2%) can be used as a 
daily mouthwash, as it is known to reduce the amount of plaque on teeth [5,36]. However, despite 
CHX reducing plaque, Cochrane review considered eight clinical trials in adolescents and children, 
to conclude it does not concurrently reduce caries [37]. In support of this, 0.2% CHX gel also did 
not reduce S. Mutans when applied to the surface of teeth in longitudinal studies [37,38]. 
Furthermore, systemic review of CHX varnishes applied to the surface of teeth also did not identify 
any strong evidence that CHX reduces rates of dental caries [39]. For caries prevention rather, 
0.05% sodium fluoride daily oral rinse is currently suggested [40,41]. 
 
Nevertheless, if mouthwash is to be utilised for plaque reduction, national guidelines state that 
mechanical tooth brushing and interdental cleaning are the preferred method for effective plaque 
removal, and that any mouthwash should be an adjunct rather than replacement for brushing 
[41,42]. The interval between tooth brushing and CHX mouthwash, should also be greater than 30 
minutes, and ideally more than 2 hours [43]. This not only because a mouthwash could potentially 
wash the fluoride from toothpaste away, but because CHX rinses may interact with the anionic 
components of many toothpastes, such as SLS and sodium monoflurophosphate, and reduce the 
beneficial effects of fluoride on the remineralisation of enamel lesions [44]. 
 
Gingivitis and periodontitis 
Gingivitis and periodontitis are ‘gum diseases’ caused by the host inflammatory response to 
bacteria at or within the gingival crevice/periodontal pocket. The most significant levels of disease 
involve Gram-negative anaerobic species, such as Porphyrmonas gingivalis, Fusobacterium 
nucleatum, Prevotella spp and Treponema denticola [45,46]. CHX is not a ubiquitous agent 
recommended for all plaque-induced gingival and periodontal diseases [47] rather, as an adjunct 
strategy for early gum disease (gingivitis) and periodontitis [48]. 
 
CHX may confer some clinical benefit in managing gingivitis, as a systematic review demonstrated 
that 4-6 weeks of daily rinsing with 0.2% CHX reduced clinical signs in several studies [34]. 
However, the recent European Federation of Periodontology (EFP) consensus guidelines make it 
clear that such antiseptic products should be used as an adjunct to mechanical tooth brushing and 
interdental cleaning [48]. The EFP guidelines also cited the most effective adjunctive agents for 















For established periodontitis, adjunctive physical or chemical agents may also be employed 
alongside mechanical measures [48,51]. The EFP guidance suggests that ‘adjunctive antiseptics 
may be considered, specifically CHX mouth rinses for a limited period of time, in periodontitis 
therapy, as adjuncts to mechanical debridement, in specific cases’. Furthermore, the EFP 
document states ‘locally administered sustained-release CHX as an adjunct to subgingival 
instrumentation in patients with periodontitis may be considered.’ This has been supported by 
systematic review from ten studies demonstrating that PeriochipTM as an adjunct to root surface 
debridement, also caused small decreases in both periodontal pocketing and clinical attachment 
loss (<1mm) [52-54].  
 
It is important to note that the EFP guidelines apply to the treatment of Stage I-III periodontitis and 
not for Stage IV (very severe) periodontitis. Related to this level of disease, Cochrane reviews 
concluded that use of 0.2% CHX mouthwash was not effective with reducing moderate to severe 
periodontitis, even as an adjunct [5,55-58]. One possible reason could be that CHX used as a 
mouth rinse does not penetrate deep periodontal pockets, where anaerobic bacteria reside and 
modulate periodontal disease, as well as shifts in the oral microbiome to bacteria associated with 
oral disease [21].  
 
Necrotising Periodontal Diseases 
Necrotizing gingivitis (and more rarely necrotizing periodontitis) is mostly observed in patients who 
are temporarily and/or moderately compromised with risk factors such as poor oral hygiene, host 
immune suppression and the accumulation of anaerobic bacteria, such as Prevotella intermedia, 
Fusobacterium, plus spirochetes such as Treponema [59,60], stress, poor nutrition and smoking 
etc. The bacteria that cause the gingiva to become inflamed and swollen are associated with 
characteristic grey sloughing and halitosis [61]. First line treatment involves oral hygiene, and 
antibiotics such as metronidazole or amoxicillin, but NICE and SDCEP guidelines currently 
recommend 0.12% or 0.2% CHX, or 6% hydrogen peroxide, mouthwashes as an adjunct [42,47]. 
This may be related to anti-bacterial effects of CHX on some Gram negative bacteria such as 
Prevotella Intermedia [62]. More clinical studies and systematic reviews however, are necessary 
before providing recommendations, especially as CHX can shift the oral microbiome to biofilms 
where Fusobacterium can predominate [63]. Rarely seen in the developed world are necrotising 
gingivitis, necrotising periodontitis, which may be seen in chronically and severely compromised 
patients with such underlying conditions such as HIV [60,61]. 
 
Peri-implantitis 
With respect to dental implants, chlorhexidine has indications at several different stages:  
 Pre-surgical mouth rinse (0.12% or 0.2% Chlorhexidine) to reduce oral microbial load for 7-












 Post-operative protocols involving application of pressure for 30 minutes with gauze soaked 
in chlorhexidine [65] and rinse and during 7-14 days after surgery to aid healing [66,67] and 
for treatment of post-operative infections;  
 Reduction of implant biofilm formation post-surgery [68] this may not necessarily relate to 
long improved outcomes in terms of preventing or managing longer term infections such as 
peri-implantitis 
 As a mouth rinse during implant maintenance and for treatment of peri-implant disease, 
where high levels of plaque control are important. Including, irrigation with 0.12-0.2% 
chlorhexidine, plus topical chlorhexidine gel for 10 days, as an adjunct to mechanical 
debridement, may be beneficial [69].  
 As a local delivery system adjunct where multi-centre trails have also suggested that 6 
months uses of PeriochipTM could reduce implant pocketing depth [70]. 
 
Current UK guidelines suggest that management of peri-implantitis could include ‘non-surgical 
debridement with carbon fibre or plastic curettes and irrigate the pocket with 0.2% CHX’ [47]. 
However, a more recent systematic review from eight studies has concluded that, the bleeding on 
probing and pockets depth reductions observed with mechanical debridement of implants alone, 
were not improved by the adjunct use of CHX over 10-14 days, either as a 0.12% and 0.2% mouth 
rinse, or a 1% gel [71].  
 
For the surgical management of peri-implantitis involving re‐contouring the implant surface, implant 
debridement and apically repositioned flap found that irrigation with 0.12% or 2% CHX as chemical 
adjunct, reduced microbial decontamination, yet did not improve clinical outcomes [72]. Further 
studies and refinements on current guidelines for management of peri-implantitis are thus needed.  
 
Oral surgery and oral medicine 
Medication-related osteonecrosis of the jaw (MRONJ), is a healing defect associated with the use 
of several groups of medications including bisphosphonates, RANKL inhibitors and anti-angiogenic 
agents [73,74]. NHS England guidelines (2015) state that 0.2% CHX mouthwash should be used 
twice daily during the week before extractions and then 24 hours post-operatively, and twice daily 
for up to 2 months to facilitate healing [75]. Elsewhere in Europe and the US, 0.12% CHX 
mouthwash has been similarly be advised 3 times a day for 7 days before, and then 15 days after, 
extractions in cancer patients at high risk of MRONJ [76]. However, NHS England guidelines have 
since been superseded by Scottish guidelines, advising not to use of CHX mouthwashes prior to 
extraction in patients categorised as either low or high risk of MRONJ, stating that there is 
insufficient evidence to support the use [74,75]. Nevertheless, CHX can also be used to treat 
MRONJ once it has developed. Indeed, the American Association of Oral and Maxillofacial 
Surgeons suggest the use of CHX mouthwash, in the early management of MRONJ (Stage 1) [77]. 













[78], and thus global agreement on the use of CHX, both prophylactically and as part of 
management, awaits full confirmation.  
 
Infective endocarditis 
Historically, CHX pre-rinses were considered for individuals who are at higher risk of infective 
endocarditis following dental procedures [79]. In 2015, NICE reviewed the evidence from 
randomised controlled trials, including studies using 10ml 0.2% CHX mouthwash for 1 minute prior 
to extraction [80-82], to conclude that pre-rinsing had no beneficial effect on any subsequent 
bacteraemia. This was supported by a more recent systematic review and meta-analysis, also 
demonstrating that CHX has little effect on the bacteraemia induced by tooth extraction [83]. In the 
UK, the updated SCDEP and latest NICE/BNF do not recommend CHX prophylaxis [80,84]. 
 
Root canal treatment 
Irreversible pulpitis and periapical periodontitis are caused by bacteria entering the root canal 
system, including Gram-positive Enterococcus faecalis, which is arguably the most resistant 
bacteria to disinfection and unresolved periapical infections [85]. Cochrane review found no 
conclusive evidence with clinical outcomes, namely pain and swelling, to advise that CHX, 
compared to other antiseptics, is the superior irrigant of choice for root canal therapy [86,87]. Data 
are conflicting however. For example, using the secondary outcome measures of microbial culture 
in vitro, 2% CHX had superior bactericidal properties to sodium hypochlorite (2.5%) on 
Enterococcus faecalis [88]. Conversely, after longer periods of irrigation for 20‐minutes, 2.5% 
sodium hypochlorite was more effective at preventing bacterial growth than 2% CHX [89]. A 
sufficient exposure time is therefore important with sodium hypochlorite use. Higher concentrations 
(5.25%) of sodium hypochlorite are also more effective than lower concentrations (1% ) [90], but 
2% sodium hypochlorite remains the irrigant of choice amongst dentists for root canal therapy, due 
to being less tissue toxic than 5.25% [90]. Furthermore, sodium hypochlorite more successfully 
dissolves inorganic matter compared to CHX, which if left compromises the quality of the seal 
within the root canal filling, leading to possible failure [91]. Nevertheless, the SDCEP suggest 0.2% 
CHX for whole mouth oral disinfection, as an adjunct to healing of perio-endo lesions after RCT 
has been completed [3,47].  
 
Tooth Extractions  
CHX is recommended by the SDCEP as a mouthwash during dental infections leading to 
periodontal abscesses [47]. However, dental abscesses are polymicrobial in nature and it is difficult 
to find any evidence as to how effective CHX is at reducing the clinical symptoms in vivo, and/or 
the mechanisms by which it may do so [92]. CHX may also sometimes be used as a mouth rinse 
post-tooth extraction, to reduce post- operative bacterial infections, even though salt water rinses 
tend now to be the first line post- operative approach [93]. Recent studies however, have 
demonstrated that pre-rinsing reduces post-operative bacteraemia after extraction, which peaks at 













post-rinse for surgical third molar extractions, supported by Cochrane review and the UK Faculty of 
General Practitioners (FGDP) [94], for rinsing either pre- or post-extraction with 0.2% CHX, or 
placing 0.12% CHX gel in the socket post extraction. This appeared to reduce clinical symptoms of 
post-operative alveolar osteitis (dry socket) by up to 58% [95-97]. This is interesting because the 
cause of alveolar osteitis is not thought to be bacterial; rather it is caused by premature disruption 
of the clot after extraction allowing bone to be exposed to the oral environment [98].   
 
Oral infections 
Denture stomatitis is a disease largely caused by the presence of the fungi Candida albicans within 
the oral cavity due to poor denture hygiene, and thus options for disinfecting dentures may include 
CHX [99]. CHX gel can also be applied 1-2 times a day to affected areas of the oral mucosa to 
treat Candidiasis and apthalous ulcers, particularly in immunocompromised patients who are more 
susceptible to overgrowth of Candida albicans [100,101], with some in vivo evidence to supporting 
its ability to reduce this fungi in saliva, biofilms and the gingival crevice [102,103]. Current 
guidelines advise the use of CHX twice daily for mucosal inflammation and ulceration with 
secondary infection relating to oral herpes simplex virus infection [3,100,104]. This guidance is 
supported by longstanding evidence that CHX mouthwash is antiviral for many enveloped viruses 
that may colonise the oral cavity, including herpes simplex virus (HSV), cytomegalovirus (CMV), 
influenza A, parainfluenza and hepatitis B (HBV) [105,106]. 
 
Pre-rinsing to reduce microbial aerosols 
In response to dental procedures, including the use of the high speed drill, 3 in 1 air and ultrasonic 
scaler, microbes can aerosolise and splatter up to 6 feet away from the dental chair [107,108]. 
Recent systematic review has demonstrated moderate evidence that pre-procedural mouth rinsing 
with antiseptics can reduce dentally generated aerosolisation of viable microbes [109]. This 
includes 0.2% CHX reducing the number of colony forming units (CFUs) of bacteria produced 
(approximately 70%) in response to ultrasonic scaling, as measured on an agar plate placed within 
the dental surgery [110-112]. Randomised controlled trials have also shown that compared to pre-
rinsing with 0.2% CHX, herbal mouth rinses are less effective - in the region of 30% [111]. 
Therefore, pre-existing 2003 CDC guidelines recommending pre-rinsing with CHX gluconate, 
essential oils, or Povidone-Iodine to reduce microorganisms in aerosols and spatter produced by 
dental procedures still appear to be appropriate [113].  
 
However, these aerosolisation studies mainly pertain to bacterial cultures. CHX may also be more 
anti-virucidal against enveloped than non-enveloped viruses [114,115], thus much research is still 
required in this area. The emerging virus Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-CoV-2), causative for the ongoing COVID-19 pandemic, also resides in the oral cavity, due 
to the high expression levels of the Angiotensin Converting Enzyme-2 receptor (ACE2) in oral soft 
tissues, as well as saliva [115-117]. Despite SARS-CoV-2 being enveloped, latest publications 













120]. We therefore advise caution assuming any benefits of CHX pre-rinses for reducing dentally-
induced aerosolisation of viruses. 1% hydrogen peroxide appears to be a more effective anti-viral 
agent and therefore, at this time, appears the pre-rinse of choice for reducing salivary load and 
aerosolisation of oral microbes [119-120]. Povidone-Iodine, 20-30% ethanol and herbal 
mouthwashes, such as Listerine, may also have some emerging evidence of antiviral properties, 






Uses in secondary care 
 
Oral cancer patients 
The Royal College of Surgeons of England (RCS, Eng.) guidance states CHX may be used prior to 
and during cancer therapy, including radiotherapy and chemotherapy of head and neck cancers 
(HNCC), or other cancers such as leukaemia, where maintaining oral hygiene and tooth brushing 
may be difficult, with the aim of reducing oral bacterial load [121]. Anecdotal evidence suggests 
CHX is not widely used within hospital maxillofacial departments for this purpose. It is more likely 
that HNCC patients may be using CHX rinses at home, due to its aforementioned claims to 
improving plaque control and reducing gingivitis [5]. There are no studies advocating the use of 
CHX to prevent caries, gingivitis and periodontal disease in HNCC patients, rather effective oral 
hygiene, and a 0.2% fluoride daily mouthwash, would be preferred, as the xerostomia-associated 
caries [122]. Oral mucositis is a recognised complication of radiotherapy for HNCC [122]. Recent 
systemic review however, did not identify benefit of CHX for reducing the clinical symptoms oral 
mucositis [123,124]. Indeed, in patients undergoing cancer chemotherapy with neutropenia who 
had developed oral mucositis, the use of CHX appeared to actually induce more mucosal 
inflammation, and elevate symptoms of mucositis [125].  
 
Inter-maxillary fixation and orthodontic devices 
It has long been established that intra-oral appliances, including inter-maxillary fixation devices and 
orthodontic appliances, impair oral hygiene and thus render patients at a higher risk of plaque 
accumulation, and in turn dental caries [126,127]. Individual studies have demonstrated that 0.2% 
CHX mouthwash can reduce plaque indices and the incidence of white spot lesions with fixed 
appliances [128,129]. However, a systematic review by Tang et al (2016), although detecting 
significant reductions in S. Mutans with CHX mouthwashes, only found weak evidence that CHX 
use related to clinical benefits with reduced caries for individuals wearing fixed orthodontic 
appliances [130]. With a different purpose, 1% CHX gel also appeared to be effective at removing 
Staphylococcus aureus from removable orthodontic retainer devices [131], perhaps mirroring 













information leaflets recommend daily alcohol-free fluoride mouth rinses, rather than CHX, for 
prevention of caries [132], and due to it’s concurrent staining associated with longer-term use. 
Therefore, at this time, it would be unlikely for dental practitioners to recommend CHX for plaque 
control with orthodontic appliances.  
 
Uses in special care dentistry 
Public Health England (PHE) figures have estimated 1 million people in the UK with learning 
disabilities, to include Downs Syndrome, autism and head injuries. Such conditions can lead to 
physical and psychological difficulties that make effective oral hygiene routines more challenging 
(PHE). Indeed there is increased caries risk, increased gingivitis and a high prevalence of 
periodontal disease amongst individuals with learning difficulties [133,134]. The British Society of 
Periodontology (BSP) also advocate that the use of ‘antiplaque agents like CHX are useful for 
managing acute periods when cleaning is difficult but not needed as a routine’ [4], such as those 
with special needs who find mechanical tooth brushing physically difficult or painful [47]. Although it 
must be noted that use of CHX mouthwash is licensed for 30 days of use [41].  
 
The most recent Clinical Guidelines for the Oral Health Care of People with Learning Disabilities 
(2012) mention the application of 1% CHX gel as a potentially effective adjunct for reducing 
periodontal disease, if applied at home daily in individuals with Down Syndrome [135]. However, 
although CHX in its various formulations may be effective in reducing gingivitis in systemically 
healthy individuals [5], for those with learning disabilities systematic review could not find any good 
evidence that CHX reduced gingivitis or periodontal disease [136]. An explanation proposed for 
this was that these individuals experienced more severe levels of gingival inflammation [136], and 
thus fluoride use with improved manual oral hygiene continue to be first line, as reported for 
healthy individuals, but with adapted techniques, tools and increased supervision [41].  
 
Evidence supporting current use and future studies 
 
The purpose of this review was to use available evidence and guidelines to highlight possible 
appropriate uses of CHX for clinical management of oral disease. In summary, there is an 
evidence base to suggest that CHX may be effective for plaque control and gingivitis, alveolar 
osteitis (not caused by microbes), prevention of bacterial aerosolisation and symptomatic 
management of some viral infections of the oral cavity. However, these indications must always be 
weighed alongside staining of teeth, emerging antimicrobial resistance and the rare anaphylactic 
reactions to CHX. Conversely, the effectiveness of CHX (alone) for preventing or managing chronic 
periodontitis, dental caries, ANUG, peri-implantitis, infections associated with extraction and 
aerosolisation of viruses is less well supported by the literature. We propose that more clinical 
studies investigating the mechanism of action of CHX on oral microorganisms in vivo are urgently 
















(using 2017 Classification/Terminology) 
 
Examples of clinical uses for CHX 
Periodontal Health & Gingival Health, 
Periodontal abscesses, endodontic-periodontal 
lesions, peri-implant health, peri-implantitis 
As a short-term adjunct to mechanical plaque control. 
During immediate post-operative phase after ressective periodontal surgery e.g. crown lengthening. 
Gingivitis: Dental Biofilm induced, Peri-implant 
mucositis 
Short-term management of plaque-induced gingival inflammation as an adjunct to mechanical plaque 
control. 
As an adjunct in management of Drug-influenced gingival enlargement / Fixed orthodontic appliance 
therapy 
Gingival Diseases: Non-dental biofilm induced Management of self-harming traumatic lesions e.g. gingivitis artefacta. 
Management of specific infections or Inflammatory and immune conditions with erosive/ulcerative tissues 
Post biopsy/excision of neoplasms 
Necrotising Periodontal Diseases As a short-term adjunct to (or temporary replacement for) mechanical plaque control. 
Periodontitis As a short-term adjunct to mechanical plaque control. 
Sub-gingival adjunctive irrigant (mouth rinse), gel or local delivery system to conventional sub-gingival 
debridement  
Following periodontal surgery  
Periodontitis as a manifestation of systemic 
disease, traumatic occlusal forces, tooth and 
prosthesis related factors 
As a short-term adjunct to mechanical plaque control. 
Sub-gingival adjunctive irrigant (mouth rinse), gel or local delivery system to conventional sub-gingival 
debridement  
Following periodontal surgery 
Systemic diseases or conditions affecting the 
periodontal supporting tissues 
As a short-term adjunct to mechanical plaque control. 
Sub-gingival adjunctive irrigant (mouth rinse), gel or local delivery system to conventional sub-gingival 
debridement  
Following periodontal surgery 
Periodontal Abscesses See periodontitis and also for pericoronal abscess / pericoronitis 
Endodontic-periodontal lesions See periodontitis 
Intra-canal irrigant where sodium hypochlorite unavailable/contraindicated 
Muco-gingival deformities and conditions As a short-term adjunct to mechanical plaque control in defect or following corrective muco-gingival surgery 
Traumatic occlusal forces See periodontitis 
Tooth and prosthesis related factors See periodontitis 
Removable prosthesis cleansing 
Peri-implant health See Periodontal Health & Gingival Health 
Peri-implant mucositis See Gingivitis: Dental Biofilm induced 
Peri-implantitis See periodontitis 
Peri-implant soft and hard tissue deficiencies As a short-term adjunct to mechanical plaque control to facilitate post-extraction healing 
 














 Key causative  
microbes 
Formulation Supporting information 
Dental caries Streptococcus Mutans 
Lactobacillus 
Not recommended May reduce prevalence of S. Mutans and amount of gingival plaque, but unlikely to 
reduce incidence of dental caries  
 
Early indications mouthwash may result in more acid saliva and microbiome shift to 




See dental caries 
 
Not recommended See dental caries 
Pre-extraction 
 
Mixed Not recommended  
 
Pre-rinsing no beneficial effect on any subsequent bacteraemia 
Post-extraction  
 
Mixed Not recommended Saltwater mouth rinse preferred post-operatively 
 
 
Dry socket None - inflammatory 0.12 or 0.2%  daily 
mouthwash 
Evidence to support use as oral rinse pre- or post-extraction, may have benefit on 







None - inflammatory Not recommended Most recent guidelines, not recommended in UK prior to extraction  
 






(most persistent)  
0.2 - 2% peri-
operative irrigant 
May have some benefit on pathogens causative for persistent periodontal periodontitis 





Mixed 10 ml of 0.12 or 
0.2% mouthwash 
for 1 minute prior to 
procedure 
Reduces aerosolisation by 70-90%  
 
 


















 Key causative  
microbes 






Streptococcus  Salivarius 
 
Not recommended Pre-rinsing no beneficial effect on any subsequent bacteraemia 












May have some virucidal properties as evidenced in vitro, but more clinical studies and 
systematic review needed  
 
More research required particularly for emerging viruses, as limited evidence for 




 Not recommended  
Viral aerosolisation 
 
 Not recommended Insufficient evidence to conclude that pre-rinse reduces aerosolisation of any viruses 
during dental procedures. More studies required 
Denture stomatitis Candida albicans 0.12 or 0.2%  daily 
mouthwash 
 




Mouthwash recommended for denture stomatitis, supported by studies confirming CHX 
reduces oral C. albicans load 
 
A number of also studies suggesting mouthwash prevents binding of Candida to teeth 






None- inflammatory Not recommended 
 
May increase mucosal inflammation  
Poor oral hygiene 
due to underlying 
condition 
Mixed Not recommended Improved oral hygiene preferred for caries prevention and to improve periodontal 
health, with 0.2% fluoride daily oral rinse if adjunct mouthwash required 
 
 
Table 3. Other systemic conditions, including oral mucosal viral and fungal conditions, where CHX could be used under current UK guidelines and 
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